COR vs MRK vs CAH Stock Comparison

Cencora, Merck and Cardinal Health Prices as of Nov 13, 2026 Peers: Industry group
COR Cencora, Inc.
$359.02 +6.8% 1M -1.8% 1Y
Market cap
$69.10B
P/E
22.6x
Revenue (TTM)
$337.40B
Div. yield
–
Drug Distribution Healthcare
2 wins
MRK Merck & Co., Inc.
$147.78 +0.3% 1M +59.0% 1Y
Market cap
$357.22B
P/E
145.6x
Revenue (TTM)
$67.38B
Div. yield
0.02%
Pharmaceuticals Healthcare
5 wins
CAH Cardinal Health Inc
$281.08 +13.4% 1M +36.4% 1Y
Market cap
$65.90B
P/E
36.2x
Revenue (TTM)
$257.75B
Div. yield
0.01%
Drug Distribution Healthcare
5 wins

Head to Head

12 decided of 12

Merck leads on 5 of the 12 questions below (Merck 5, Cardinal Health 5, Cencora 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCORMRKCAHLeader
Larger companyMarket capitalisation $69.10B $357.22B $65.90B MRK
Cheaper on earningsLower P/E, profitable companies only 22.6x 145.6x 36.2x COR
Cheaper on forward earningsLower price / next fiscal year consensus EPS 18.8x 56.6x 22.8x COR
Faster revenue growthRevenue growth, trailing twelve months +5.0% +4.9% +10.0% CAH
More profitableNet margin, trailing twelve months — 3.6% 0.7% MRK
Better return on capitalReturn on invested capital — 2.5% 36.5% CAH
Less leveragedLower net debt / EBITDA — 3.6x 1.0x CAH
Higher dividend yieldTrailing dividend yield 0.00% 0.02% 0.01% MRK
Better 1-year returnPrice return, last 12 months -1.8% +59.0% +36.4% MRK
Better 5-year returnAnnualised price return, 5 years +23.4%/yr +12.0%/yr +40.5%/yr CAH
Less volatileAnnualised volatility, 1 year 33.4% 29.6% 25.9% CAH
Higher overall scoreMean of the five percentile scores vs peers 56/100 61/100 60/100 MRK

Percentile Scorecard

CORMRKCAH

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCORMRKCAH
Valuation 54 #13 of 27 85 #97 of 660 77 #7 of 27
Growth 64 #10 of 26 30 #434 of 619 68 #9 of 26
Profitability 64 #10 of 26 90 #59 of 595 60 #11 of 26
Financial Health – 21 #538 of 683 40 #16 of 26
Shareholder Returns 41 #11 of 18 79 #98 of 459 53 #9 of 18
Overall 56 61 60
  • COR ranked among 27 companies in Healthcare Payers and Distributors
  • MRK ranked among 695 companies in Pharmaceuticals and Biotechnology
  • CAH ranked among 27 companies in Healthcare Payers and Distributors

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCORMRKCAHSPY
1 month +6.8%+0.3%+13.4% -2.0%
3 months +14.4%+8.8%+19.5% -2.8%
6 months +39.3%+32.7%+44.0% +2.0%
Year to date +6.3%+40.4%+36.8% +10.6%
1 year -1.8%+59.0%+36.4% +12.2%
3 years +84.7%+44.6%+173.2% +68.1%
3 years, per year +22.7%+13.1%+39.8% +18.9%
5 years +186.4%+75.9%+446.4% +61.4%
5 years, per year +23.4%+12.0%+40.5% +10.1%
10 years +354.9%+131.1%+293.8% +248.5%
10 years, per year +16.4%+8.7%+14.7% +13.3%

Risk

MeasureCORMRKCAHSPY
Volatility, 1Y 33.4%29.6%25.9% 13.6%
Downside volatility, 1Y 40.0%24.1%24.8% 13.9%
Beta vs S&P 500, 1Y 0.050.20-0.01 1.00
Return / volatility, 1Y -0.051.991.41 0.90
Max drawdown, 5Y -32.6%-44.7%-21.0% -25.4%
From 52-week high -4.2%-5.5%0.0% -3.2%
52-week high $374.75$156.45$281.08 $779.14
52-week low $252.74$92.86$182.50 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCORMRKCAH
P/E now vs peer median 22.6xmedian 25.2x 148.7xmedian 17.0x 35.9xmedian 25.2x
P/S now vs peer median 0.2xmedian 0.4x 5.4xmedian 8.4x 0.3xmedian 0.4x
EV/EBITDA now vs peer median —median 14.5x 33.7xmedian 14.6x 18.7xmedian 14.5x
P/FCF now vs peer median 14.5xmedian 16.5x 24.7xmedian 19.0x 13.3xmedian 16.5x
P/B now vs peer median 18.6xmedian 2.7x 8.1xmedian 2.0x -21.5xmedian 2.7x
PEG now vs peer median —median 1.72 -8.16median 0.43 0.40median 1.72

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCORMRKCAH
Revenue $337.40B $67.38B $257.75B
Gross profit $13.87B $48.35B $10.05B
Operating income $3.93B $4.76B $2.70B
Net income $3.51B $2.45B $1.82B
Free cash flow – $14.75B $4.90B
R&D – $30.76B –
EPS (diluted) – $0.99 $7.80
Cash & equivalents $4.88B $9.55B $5.26B
Total debt – $53.78B $8.82B
Shares (diluted) 193.94M 2.48B 233.00M
Enterprise value $69.10B $320.16B $49.06B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCORMRKCAH
P/E 22.6x 148.7x 35.9x
P/FCF 14.5x 24.7x 13.3x
P/Operating cash flow 14.3x 19.5x 11.6x
P/S 0.2x 5.4x 0.3x
P/B 18.6x 8.1x -21.5x
P/Tangible book 18.6x 17.8x -21.5x
EV/EBITDA – 33.7x 18.7x
EV/EBIT – 85.8x 25.4x
EV/Revenue 0.2x 6.1x 0.3x
EV/FCF – 27.7x 14.0x
EV/Operating cash flow 14.3x 21.8x 12.2x
PEG (3Y EPS CAGR) – -8.16 0.40

Growth

14 metrics
MetricCORMRKCAH
Revenue growth (1Y) 5.0% 4.9% 10.0%
Revenue CAGR (3Y) 8.8% 4.3% 7.1%
Gross profit growth (1Y) 20.8% -2.5% 17.1%
Gross profit CAGR (3Y) 15.7% 3.8% 12.6%
Operating income growth (1Y) 49.5% -78.2% 13.6%
Operating income CAGR (3Y) 18.9% -13.9% 63.6%
Net income growth (1Y) 124.0% -87.1% 13.6%
Net income CAGR (3Y) 26.3% -19.1% 86.5%
EPS growth (1Y) – -87.0% 16.9%
EPS CAGR (3Y) – -18.2% 90.8%
Operating cash flow growth (1Y) 23.6% 9.6% 11.6%
Operating cash flow CAGR (3Y) 7.0% 2.9% 18.7%
Free cash flow growth (1Y) – 13.0% 10.1%
Free cash flow CAGR (3Y) – 3.8% 19.9%

Profitability

14 metrics
MetricCORMRKCAH
Gross margin – 71.8% 3.9%
EBITDA margin – 18.0% 1.4%
Operating margin – 7.1% 1.0%
Pretax margin – 7.1% 0.9%
Net margin – 3.6% 0.7%
FCF margin – 21.9% 1.9%
Operating cash flow margin 1.4% 27.8% 2.2%
Return on equity 101.2% 5.6% –
Return on assets 4.1% 1.9% 3.1%
Return on invested capital – 2.5% 36.5%
Return on capital employed – 4.6% 22.3%
Asset turnover 3.9x 0.5x 4.4x
Cash conversion (OCF / net income) 1.4x 7.6x 3.1x
Stock comp / revenue – 1.6% 0.1%

Financial Health

11 metrics
MetricCORMRKCAH
Debt / assets – 40.5% 14.8%
Debt / equity – 1.2x -2.9x
Net debt / EBITDA – 3.6x 1.0x
Debt / FCF – 3.6x 1.8x
Liabilities / assets – 66.1% 105.1%
Equity / assets 4.2% 33.9% -5.1%
Interest coverage – – 7.9x
Current ratio 0.9x 1.4x 0.9x
Quick ratio – 0.8x 0.4x
Cash ratio – 0.3x 0.1x
Altman Z-score – 3.90 5.05

Shareholder Returns

7 metrics
MetricCORMRKCAH
Dividend yield 0.9% 2.3% 0.7%
Net buyback yield – 0.8% 2.3%
Shareholder yield 0.9% 3.1% 3.0%
Payout ratio (earnings) – 341.6% 26.8%
Payout ratio (FCF) – 56.7% 10.0%
Dividend growth (1Y) – 3.2% -1.4%
Dividend CAGR (3Y) – 4.4% -1.7%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCORMRKCAH
Forward P/E 18.8xFY2027 56.6xFY2026 22.8xFY2027
EPS, next fiscal year $19.07FY2027 $2.61FY2026 $12.31FY2027
EPS growth, next FY +6.1%FY2027 -70.9%FY2026 +9.3%FY2027
EPS growth, the year after +17.4% +228.7% +12.8%
Revenue, next fiscal year $328.27BFY2027 $69.66BFY2026 $273.40BFY2027
Revenue growth, next FY -2.7%FY2027 +7.2%FY2026 +7.5%FY2027
Revenue growth, the year after +19.1% -4.6% -3.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCORMRKCAH
Held by institutions 94.7% 79.9% 87.4%
Institutions holding 1,345 3,804 1,494
Change in shares held, QoQ +15.7% +2.6% +2.8%
Institutions buying 542 1,844 711
Institutions selling 612 1,469 559
Buyers to sellers 0.89 1.26 1.27

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CORMRKCAH
COR 1.00 0.20 0.62
MRK 0.20 1.00 0.28
CAH 0.62 0.28 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, COR, MRK and CAH?

Merck (MRK) is the largest by market capitalisation: Cencora (COR) $69.10B, Merck (MRK) $357.22B, Cardinal Health (CAH) $65.90B.

Which stock is cheaper, COR, MRK and CAH?

Cencora (COR) trades on the lowest price-to-earnings ratio (Cencora (COR) 22.6x, Merck (MRK) 145.6x, Cardinal Health (CAH) 36.2x). On next year's consensus earnings, Cencora (COR) is cheapest (Cencora (COR) 18.8x, Merck (MRK) 56.6x, Cardinal Health (CAH) 22.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Cardinal Health (CAH) grew revenue fastest over the trailing twelve months: Cencora (COR) +5.0%, Merck (MRK) +4.9%, Cardinal Health (CAH) +10.0%.

Which company is more profitable?

Merck (MRK) has the highest net margin (Merck (MRK) 3.6%, Cardinal Health (CAH) 0.7%). On return on invested capital, Cardinal Health (CAH) leads (Merck (MRK) 2.5%, Cardinal Health (CAH) 36.5%).

Which stock has performed better?

Over the past year Merck (MRK) returned the most: Cencora (COR) -1.8%, Merck (MRK) +59.0%, Cardinal Health (CAH) +36.4%. Over five years, Cardinal Health (CAH) compounded fastest (Cencora (COR) +23.4%/yr, Merck (MRK) +12.0%/yr, Cardinal Health (CAH) +40.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Merck (MRK) has the highest dividend yield: Cencora (COR) 0.00%, Merck (MRK) 0.02%, Cardinal Health (CAH) 0.01%. Cencora (COR) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Cardinal Health (CAH) has been the steadiest (Cencora (COR) 33.4%, Merck (MRK) 29.6%, Cardinal Health (CAH) 25.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, COR, MRK and CAH?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Merck (MRK) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.